Answers are grounded in this paper and cite their sources.
The incorporation of orally administered 1-14C-alpha-ketoisocaproate into the leucine of proteins in rats was compared with the incorporation of [3H]leucine itself administered simultaneously and expressed as a ratio, R. This ratio in whole body protein has been shown to be approximately equal to the nutritional efficiency of alpha-ketoisocaproate as a dietary substitute for leucine. In normal rats on a 14% protein diet, R in whole body protein (0.30 +/- 0.01) and in the protein of various organs was the same whether the isotopes were given by single injection or 6-hr constant infusion. Thus, both techniques yield the same time-independent parameter, R, which measures the relative efficiency of alpha-ketoisocaproate as a substitute for leucine. R varied between organs as follows: liver (0.22 +/- 0.01) less than kidney less than heart less than salivary gland less than brain less than muscle (0.42 +/- 0.01). In rats with galactosamine-induced acute liver failure (Group I), carbon tetrachloride-induced cirrhosis (Group II), or portal-systemic shunts (Group III), whole body protein R and R in the protein of organs other than the liver was generally increased compared with controls, as was R in circulating IgG in Group III; R in liver protein was unchanged (Groups II and III) or slightly lower than controls (Group I). Thus, severe liver disease and portal-systemic shunting both increase the utilization of alpha-ketoisocaproate for synthesis of protein in the body as a whole and in most organs. In the liver, however, alpha-ketoisocaproate utilization for protein synthesis is unaffected or slightly reduced.
No takes yet. Share an insight, caveat, or question.
Muñoz et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: